Case presentation: A 59-yearold man with a history of hypertension, dyslipidemia, and smoking was hospitalized with acute coronary syndrome requiring emergency percutaneous coronary intervention with 4 drug-eluting stents. His discharge medications included dual antiplatelet therapy with aspirin 325 mg/d and clopidogrel 75 mg/d. Three weeks after discharge, he returned to the Emergency Departme...

The past 20 years have seen substantial advances in the shortand long-term outcomes for patients after acute coronary syndromes (ACS). Improvements in therapy and adherence to guidelines have resulted in a reduction in hospital mortality from 10.4% in 1994 to 6.3% in 2006. Despite this, 17% of patients surviving an ACS event would experience recurrent events without secondary prophylaxis, and e...

Antiplatelet therapy is the cornerstone for the secondary prevention in acute ischemic stroke. Aspirin was considered first-line therapy for secondary prevention in patients with atherothrombotic stroke. However, several studies actually found that aspirin alone did not significantly regulate platelet activation or aggregation in acute ischemic stroke. Thus, a rational approach, to augment this...